HK1255850A1 - 5-ht2c受体激动剂和组合物及使用方法 - Google Patents
5-ht2c受体激动剂和组合物及使用方法 Download PDFInfo
- Publication number
- HK1255850A1 HK1255850A1 HK18114926.0A HK18114926A HK1255850A1 HK 1255850 A1 HK1255850 A1 HK 1255850A1 HK 18114926 A HK18114926 A HK 18114926A HK 1255850 A1 HK1255850 A1 HK 1255850A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- disorders
- sleep
- addiction
- antipsychotic
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199382P | 2015-07-31 | 2015-07-31 | |
| US62/199,382 | 2015-07-31 | ||
| PCT/US2016/044426 WO2017023679A1 (en) | 2015-07-31 | 2016-07-28 | 5-ht2c receptor agonists and compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1255850A1 true HK1255850A1 (zh) | 2019-08-30 |
Family
ID=56684262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18114926.0A HK1255850A1 (zh) | 2015-07-31 | 2016-07-28 | 5-ht2c受体激动剂和组合物及使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10272094B2 (https=) |
| EP (1) | EP3328835B1 (https=) |
| JP (1) | JP6789578B2 (https=) |
| KR (1) | KR20180031035A (https=) |
| CN (1) | CN108137508B (https=) |
| AU (1) | AU2016302755B2 (https=) |
| BR (1) | BR112018001707A2 (https=) |
| CA (1) | CA3002525A1 (https=) |
| EA (1) | EA039412B1 (https=) |
| HK (1) | HK1255850A1 (https=) |
| IL (1) | IL257107B (https=) |
| MA (1) | MA42527A (https=) |
| MX (1) | MX375045B (https=) |
| WO (1) | WO2017023679A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA42527A (fr) * | 2015-07-31 | 2021-04-07 | Arena Pharm Inc | Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN110668951B (zh) * | 2018-12-21 | 2022-09-30 | 安徽贝克生物制药有限公司 | 一种盐酸司来吉兰的合成工艺 |
| CN110642721B (zh) * | 2018-12-21 | 2022-09-30 | 安徽贝克生物制药有限公司 | 盐酸司来吉兰的制备方法 |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| WO2023279012A2 (en) * | 2021-06-29 | 2023-01-05 | Tusimple, Inc. | Systems and methods for operating an autonomous vehicle |
| US12311973B2 (en) | 2021-10-14 | 2025-05-27 | Tusimple, Inc. | Systems and methods for operating an autonomous vehicle |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5180733A (en) * | 1990-03-30 | 1993-01-19 | Abbott Laboratories | Biogenic amine uptake inhibitors |
| WO1992018005A1 (en) | 1991-04-16 | 1992-10-29 | National Institutes Of Health | Method of treating trichotillomania and onychophagia |
| WO2003086303A2 (en) | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| TW200307682A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| CN1805938B (zh) * | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
| DE602004023100D1 (de) * | 2003-10-08 | 2009-10-22 | Lilly Co Eli | Verbindungen und verfahren zur behandlung von dyslipidemie |
| EP2510949A4 (en) * | 2009-12-11 | 2013-11-13 | Astellas Pharma Inc | THERAPEUTICS FOR FIBROMYALGIA |
| JP6198715B2 (ja) * | 2012-03-06 | 2017-09-20 | 武田薬品工業株式会社 | 三環性化合物 |
| AR092568A1 (es) * | 2012-09-14 | 2015-04-22 | Abbvie Deutschland | Derivados triciclicos de quinolinas y de quinoxalinas |
| MA42527A (fr) * | 2015-07-31 | 2021-04-07 | Arena Pharm Inc | Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation |
-
2016
- 2016-07-28 MA MA042527A patent/MA42527A/fr unknown
- 2016-07-28 EA EA201890402A patent/EA039412B1/ru unknown
- 2016-07-28 BR BR112018001707A patent/BR112018001707A2/pt active Search and Examination
- 2016-07-28 AU AU2016302755A patent/AU2016302755B2/en not_active Ceased
- 2016-07-28 WO PCT/US2016/044426 patent/WO2017023679A1/en not_active Ceased
- 2016-07-28 JP JP2018504658A patent/JP6789578B2/ja not_active Expired - Fee Related
- 2016-07-28 US US15/748,205 patent/US10272094B2/en active Active
- 2016-07-28 EP EP16751083.3A patent/EP3328835B1/en active Active
- 2016-07-28 MX MX2018001380A patent/MX375045B/es active IP Right Grant
- 2016-07-28 CN CN201680058247.6A patent/CN108137508B/zh not_active Expired - Fee Related
- 2016-07-28 KR KR1020187005698A patent/KR20180031035A/ko not_active Withdrawn
- 2016-07-28 CA CA3002525A patent/CA3002525A1/en not_active Abandoned
- 2016-07-28 HK HK18114926.0A patent/HK1255850A1/zh unknown
-
2018
- 2018-01-23 IL IL257107A patent/IL257107B/en active IP Right Grant
-
2019
- 2019-03-12 US US16/299,880 patent/US10624900B2/en active Active
-
2020
- 2020-04-14 US US16/848,013 patent/US11395824B2/en active Active
-
2022
- 2022-06-10 US US17/837,622 patent/US20230055376A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018001707A2 (pt) | 2018-09-18 |
| NZ739883A (en) | 2021-03-26 |
| US10272094B2 (en) | 2019-04-30 |
| AU2016302755B2 (en) | 2020-09-10 |
| EA039412B1 (ru) | 2022-01-25 |
| IL257107A (en) | 2018-03-29 |
| EP3328835A1 (en) | 2018-06-06 |
| CA3002525A1 (en) | 2017-02-09 |
| KR20180031035A (ko) | 2018-03-27 |
| AU2016302755A1 (en) | 2018-03-15 |
| US20200078368A1 (en) | 2020-03-12 |
| US20230055376A1 (en) | 2023-02-23 |
| MX375045B (es) | 2025-03-06 |
| MX2018001380A (es) | 2018-06-15 |
| EP3328835B1 (en) | 2022-10-12 |
| US10624900B2 (en) | 2020-04-21 |
| US11395824B2 (en) | 2022-07-26 |
| CN108137508B (zh) | 2021-08-27 |
| MA42527A (fr) | 2021-04-07 |
| WO2017023679A1 (en) | 2017-02-09 |
| JP6789578B2 (ja) | 2020-11-25 |
| EA201890402A1 (ru) | 2018-09-28 |
| IL257107B (en) | 2021-03-25 |
| US20200383993A1 (en) | 2020-12-10 |
| CN108137508A (zh) | 2018-06-08 |
| JP2018522025A (ja) | 2018-08-09 |
| US20180214455A1 (en) | 2018-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1255850A1 (zh) | 5-ht2c受体激动剂和组合物及使用方法 | |
| MX2020005898A (es) | Derivados de hexahidro-[1,4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor. | |
| NZ750469A (en) | 5-ht2c receptor agonists and compositions and methods of use | |
| MX2020002060A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos. | |
| GEP20227387B (en) | Methods and compositions for treating sleep apnea | |
| EP3862362A3 (en) | Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression | |
| EP3715457A3 (en) | Modulation of prekallikrein (pkk) expression | |
| MA39763A (fr) | Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci | |
| SI1781787T1 (sl) | Zdravljenje očesnih nepravilnosti, kakakterističnih za povišan očesni tlak s sirna | |
| MA32889B1 (fr) | Composes de pyrazine comme inhibiteurs de phosphodiesterase 10 | |
| PH12012500674A1 (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| MX2010007392A (es) | Antagonistas de trpa1. | |
| TW200801013A (en) | Substituted benzofused derivatives and their use as vanilloid receptor ligands | |
| EP3856182A4 (en) | Compositions and methods for treating disorders ameliorated by muscarnic receptor activation | |
| WO2010091894A3 (en) | Methods of treating hair related conditions | |
| TN2011000379A1 (en) | [1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors | |
| MX2010010303A (es) | Nuevos compuestos de acido ribonucleico de pequeña interferencia para inhibir rtp801. | |
| MY157319A (en) | Inhibitors of protein tyrosine kinase activity | |
| WO2009067243A8 (en) | Modulation of cd40 expression | |
| MX363632B (es) | Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos. | |
| MX2014003883A (es) | Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados. | |
| AR098271A1 (es) | Agonistas del receptor 5-ht₂c | |
| CL2008003895A1 (es) | Compuestos derivados de 5-o-sustituido 3-n-fenil-1,3,4-oxadiazolonas, composicion farmaceutica, proceso de preparacion, y su uso para el tratamiento de un trastorno influenciado positivamente por la inhibicion de faah tal como trastornos alimenticios y patologias neurologicas y psiquiatricas, entre otras. | |
| WO2007100631A3 (en) | Compositions and methods for modulating cytokine production | |
| WO2010083241A3 (en) | 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders |